Silence Therapeutics (SLN) Stock Rises on Cantor Fitzgerald Upgrade

AI Summary

Silence Therapeutics (SLN) saw a notable increase in stock price following an upgrade from Cantor Fitzgerald. The financial institution has expressed positive sentiment towards the company, which could influence investor confidence and market activity. Upgrades by reputable firms often lead to increased trading volumes, as traders react to the newfound optimism. This event could position SLN for a potential upswing in valuation and investor interest in upcoming quarters.